Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Champions Oncology (CSBR) EBITDA (2016 - 2025)

Historic EBITDA for Champions Oncology (CSBR) over the last 16 years, with Q4 2025 value amounting to $185000.0.

  • Champions Oncology's EBITDA fell 7472.68% to $185000.0 in Q4 2025 from the same period last year, while for Oct 2025 it was $2.2 million, marking a year-over-year increase of 37318.93%. This contributed to the annual value of $4.6 million for FY2025, which is 16189.51% up from last year.
  • Per Champions Oncology's latest filing, its EBITDA stood at $185000.0 for Q4 2025, which was down 7472.68% from -$527000.0 recorded in Q3 2025.
  • In the past 5 years, Champions Oncology's EBITDA registered a high of $4.5 million during Q1 2025, and its lowest value of -$2.6 million during Q1 2024.
  • For the 5-year period, Champions Oncology's EBITDA averaged around -$372950.0, with its median value being -$277500.0 (2022).
  • In the last 5 years, Champions Oncology's EBITDA soared by 365714.29% in 2021 and then tumbled by 2802857.14% in 2023.
  • Over the past 5 years, Champions Oncology's EBITDA (Quarter) stood at $263000.0 in 2021, then crashed by 97.34% to $7000.0 in 2022, then tumbled by 28028.57% to -$2.0 million in 2023, then soared by 137.44% to $732000.0 in 2024, then plummeted by 74.73% to $185000.0 in 2025.
  • Its EBITDA stands at $185000.0 for Q4 2025, versus -$527000.0 for Q3 2025 and -$2.0 million for Q2 2025.